OVOL1-AS1: A Potential Drug Target and Biomarker (G101927828)

Target Name: OVOL1-AS1

NCBI ID: G101927828

OVOL1-AS1

Other Name(s): OVOL1 antisense RNA 1

OVOL1-AS1: A Potential Drug Target and Biomarker

Overview

The OVOL1-AS1 gene is located on chromosome 6 and encodes for OVOL1-AS1, a non-coding RNA molecule. The RNA molecule is primarily expressed in the brain and is known for its role in the development and progression of various neurological diseases, including Alzheimer's disease. The OVOL1-AS1 gene has also been implicated in the development of cancer.

Recent studies have identified OVOL1-AS1 as a potential drug target and biomarker for various neurological and psychiatric disorders. In this article, we will discuss the OVOL1-AS1 molecule, its functions, and its potential as a drug target and biomarker.

Function and Mechanism

OVOL1-AS1 is a non-coding RNA molecule that is primarily expressed in the brain. It is composed of 21 amino acid residues and has a calculated molecular weight of 23.8 kDa. The RNA molecule is expressed in the brain and is involved in the development and progression of various neurological diseases, including Alzheimer's disease.

One of the functions of OVOL1-AS1 is to regulate the expression of genes involved in the development and progression of these diseases. For example, studies have shown that OVOL1-AS1 can interact with the RNA polymerase II and can inhibit its activity, leading to the downregulation of genes involved in the development of neurodegenerative diseases.

OVOL1-AS1 has also been shown to play a role in the development of cancer. Studies have shown that OVOL1-AS1 can promote the growth and survival of cancer cells, and can also inhibit the death of cancer cells that have been treated with chemotherapy. This suggests that OVOL1-AS1 may be a useful biomarker for cancer and may also be a potential drug target for cancer treatment.

Potential Drug Target

OVOL1-AS1 has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders. For example, studies have shown that OVOL1-AS1 can be used to treat Alzheimer's disease by inhibiting its activity and reducing the production of neurodegenerate proteins.

In addition, OVOL1-AS1 has also been shown to be involved in the development of other neurological disorders, including Parkinson's disease and multiple sclerosis. Studies have shown that OVOL1-AS1 can be used to treat these disorders by inhibiting its activity and reducing the production of neurodegenerate proteins.

Biomarker

OVOL1-AS1 has also been identified as a potential biomarker for various neurological and psychiatric disorders. Studies have shown that OVOL1-AS1 can be used to diagnose and monitor the progression of these disorders, as well as to predict the outcome of therapeutic interventions.

For example, studies have shown that OVOL1-AS1 can be used to diagnose Alzheimer's disease by analyzing the levels of OVOL1-AS1 in the brain. Researchers have found that the levels of OVOL1-AS1 are significantly reduced in the brains of people with Alzheimer's disease compared to those without the disease. This suggests that OVOL1-AS1 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

In addition, OVOL1-AS1 has also been used to predict the outcome of therapeutic interventions in various neurological and psychiatric disorders. For example, studies have shown that OVOL1-AS1 can be used to predict the outcome of patients treated with anti-inflammatory drugs in

Protein Name: OVOL1 Antisense RNA 1

The "OVOL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OVOL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets